Cantor Fitzgerald set a $96.00 price objective on Global Blood Therapeutics (NASDAQ:GBT) in a research report sent to investors on Monday morning. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently commented on GBT. JPMorgan Chase & Co. reiterated a buy rating and set a $75.00 target price on shares of Global Blood Therapeutics in a report on Sunday, August 5th. SunTrust Banks set a $70.00 target price on Global Blood Therapeutics and gave the company a buy rating in a report on Sunday, August 5th. Piper Jaffray Companies initiated coverage on Global Blood Therapeutics in a report on Monday, August 6th. They set an overweight rating and a $80.00 target price on the stock. Wedbush reiterated an outperform rating and set a $73.00 target price on shares of Global Blood Therapeutics in a report on Monday, August 6th. Finally, BidaskClub upgraded Global Blood Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $83.20.

Shares of NASDAQ:GBT opened at $45.45 on Monday. Global Blood Therapeutics has a one year low of $30.15 and a one year high of $68.05.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Tuesday, November 6th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.02. During the same period in the previous year, the company earned ($0.66) EPS. As a group, research analysts anticipate that Global Blood Therapeutics will post -3.36 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board increased its holdings in Global Blood Therapeutics by 40.6% during the 2nd quarter. State of Wisconsin Investment Board now owns 52,300 shares of the company’s stock worth $2,364,000 after purchasing an additional 15,100 shares during the last quarter. Nexthera Capital LP increased its holdings in Global Blood Therapeutics by 28.2% during the 2nd quarter. Nexthera Capital LP now owns 404,092 shares of the company’s stock worth $18,265,000 after purchasing an additional 88,945 shares during the last quarter. Botty Investors LLC increased its holdings in shares of Global Blood Therapeutics by 45.7% in the 3rd quarter. Botty Investors LLC now owns 129,435 shares of the company’s stock valued at $4,919,000 after acquiring an additional 40,595 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $2,680,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Global Blood Therapeutics by 19.7% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 23,669 shares of the company’s stock valued at $1,070,000 after acquiring an additional 3,900 shares during the last quarter.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.